Scholar Rock Holding Corporation (SRRK)
SRRKNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$51.99
+5.49 (+11.81%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $6.28bn
- P/E
- –
- EPS, last 4 quarters
- $-3.45
- Dividend yield
- –
- Day range
- –
- 52-week range
- $27.07 to $61.76
- Average volume
- 1.83m
- Previous close
- $46.50
Analysts
15 coveringBuy14 buy, 1 hold, 0 sell
Targets a year out average $69.67, +34.0% from here
Earnings
next estimate $-0.8700Next report Nov 10, 2026
Sep 2025
-2.3%
Dec 2025
-2.3%
Mar 2026
-1.2%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$103.55m | -$91.90m | -$102.02m | -$108.90m |
| Net income | -$102.22m | -$90.97m | -$105.51m | -$109.90m |
News
8 latest- Wednesday 10/28 Insider Buying Report: LRN, SRRK BNK Invest · Oct 28, 2026
- FDA Drug Approvals In September 2026 RTTNews · Oct 16, 2026
- Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval RTTNews · Oct 8, 2026
- Scholar Rock Resubmits Marketing Authorisation Application For Apitegromab RTTNews · Oct 8, 2026
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead RTTNews · Sep 18, 2026
- Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA RTTNews · Sep 12, 2026
- Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab RTTNews · Sep 2, 2026
- Biotech Stocks Facing FDA Decision In September 2026 RTTNews · Aug 26, 2026
The company
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- scholarrock.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.